DAREONTM-9, a phase Ib study of obrixtamig plus topotecan in patients (pts) with advanced small cell lung cancer (SCLC): Interim analysis results. Comprehensive longitudinal immune cell monitoring in ...
Subgroup analysis in clinical trials constitutes a vital methodological tool to uncover differential treatment effects within specified categories of patients. This approach enables researchers to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback